Aurinia Pharmaceuticals Inc. (AUPH) Stock Price & Analysis

Aurinia Pharmaceuticals Inc. (AUPH) rose 0.00% to USD 15.35 as of July 25, 2026 at 04:37 UTC, according to Nexqual real-time market data.

AUPH last closed at USD 15.35; the session ranged USD 15.13–15.52 on volume of 742,140 shares. Market capitalization is —, with a 52-week range of USD 8.8–19.25 (NGM). Source: Nexqual, July 25, 2026 at 04:37 UTC.

Key Statistics (as of July 25, 2026 at 04:37 UTC)

Technical Analysis (AUPH)

Nexqual's technical model rates AUPH "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:37 UTC.

From Aurinia Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• During the first 4 years of the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application ("ANDA") or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all of the data required for approval.
• Importantly, the patent claims reflect the unique and proprietary dosing regimen of LUPKYNIS that is consistent with the FDA-approved product label.
• Reddy's Laboratories, Inc., DifGen Pharmaceuticals LLC and Sandoz Inc. advising that each company had submitted an Abbreviated New Drug Application ("ANDA") to the FDA seeking authorization to manufacture, use or sell a generic version of LUPKYNIS in the U.S., prior to the expiry of U.S.
• We maintain confidentiality agreements with potential and existing manufacturers to protect our proprietary rights related to LUPKYNIS.

Partnerships

• In August 2022, Aurinia entered into a commercial supply agreement with Otsuka to: (i) supply LUPKYNIS inventory to Otsuka at cost, plus a margin; and (ii) provide manufacturing and other services, including sharing the capacity of a dedicated manufacturing facility at Lonza Ltd. ("Lonza"), Aurinia's contract manufacturing partner for voclosporin.
• In December 2020, Aurinia entered into a manufacturing services agreement with Lonza for the construction of a dedicated manufacturing facility for voclosporin (the "Monoplant").

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:37 UTC. This page is informational and not investment advice.